[Clinical applications of recombinant complement inhibitors].
The complement system constitutes an important part of the innate immune system. Complement activation leads to the generation of C3a, C4a and C5a anaphylatoxins and the membrane attack complex. The anaphylatoxins mediate multiple reactions in the acute inflammatory response. Membrane attack complex inserts molecules into target membranes and causes cell lysis. The complement system can not discriminate between self and non-self cells and the inappropriate complement activation may lead to host cell damage. This destructive activity is tightly regulated by family of structurally and functionally related soluble and membrane-bound proteins, which act as inhibitors of complement system. The inappropriate complement activation plays an essential role in the pathogenesis of many diseases. In the therapy of these diseases specific recombinant complement inhibitors can be used. Recombinant complement inhibitors can be produced in large amounts by different eukaryotic or prokaryotic systems. The choice of the system depends on kind of the post-translational modifications of proteins.
Lipiński
Daniel
D
Instytut Genetyki Człowieka PAN, Poznań. lipin1@poczta.onet.pl
Pławski
Andrzej
A
Juzwa
Wojciech
W
Zeyland
Joanna
J
Słomski
Ryszard
R
D000706:Anaphylatoxins / Q000096:biosynthesis*; D000818:Animals; D015926:Complement C3a / Q000096:biosynthesis; D015934:Complement C4a / Q000096:biosynthesis; D015936:Complement C5a / Q000096:biosynthesis; D003169:Complement Inactivator Proteins / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D000706:Anaphylatoxins; D003169:Complement Inactivator Proteins; D011994:Recombinant Proteins; D015926:Complement C3a; D015934:Complement C4a; D015936:Complement C5a